查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1874264

siRNA药物：全球市场份额和排名、总收入和需求预测（2025-2031年）

siRNA Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 97 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球 siRNA 药物市场规模估计为 24.43 亿美元，预计到 2031 年将达到 162.38 亿美元，在预测期（2025-2031 年）内复合年增长率为 28.9%。

小干扰RNA（siRNA），也称为短干扰RNA或定序RNA，是一种双股RNA，最初被认为是非编码RNA分子。其长度通常为20-24个碱基对（常见为21个碱基对），在RNA干扰（RNAi）路径中发挥与微型RNA （miRNA）相似的作用。 siRNA在基因静默和基因表现调控中扮演重要角色。近年来，基于siRNA的疗法因其能够靶向特定基因治疗癌症、遗传性疾病、病毒感染疾病和神经退化性疾病等疾病而备受关注。 siRNA药物产品的研究范围涵盖多个方面，包括其设计、开发、测试和监管核准。

siRNA药物的主要生产商包括Alnylam、诺华、诺和诺德、健赞和Arrowhead。从消费地区来看，美国是最大的消费市场，约占全球市场份额的57%，其次是欧洲。按产品类型划分，皮下注射是最大的细分市场，市占率超过77%。依产品应用领域划分，神经系统治疗是最大的应用市场，市占率约占52%。

对siRNA药物市场驱动因素的深入分析

一、技术突破：从实验室到临床

交付系统创新

脂质奈米颗粒（LNP）技术的最佳化：早期siRNA药物由于递送效率低、标靶化差，应用范围仅限于罕见疾病领域。近年来，诸如改进的可电离脂质成分和PEG修饰等技术突破，使得LNP能够递送至肝臟（例如Alnylam公司的Onpattro）并穿过血脑障壁（例如Denali公司的RVT-1201），显着拓展了其适应症范围。

GalNAc偶联技术的广泛应用：该技术透过与去唾液酸糖蛋白受体结合，实现高效的肝臟标靶递送，减少给药频率（例如，诺华的Leqvio皮下注射每六个月一次），并促进siRNA渗透到心血管和代谢疾病等慢性疾病中。

成熟的化学改质技术

增强稳定性：2'-O-甲基修饰和硫代磷酸酯骨架等技术可将siRNA的半衰期延长至数週，并降低免疫抗原性风险。

减少脱靶效应：人工智慧辅助序列设计（例如 Sirnaomics 的人工智慧演算法）结合生物资讯筛检可提高 siRNA 特异性，从而显着提高临床安全性。

2. 市场需求：未满足的临床需求的出现

适应症范围从罕见疾病扩大到常见疾病。

慢性病治疗领域的突破：全球约有10亿人患有心血管疾病，高胆固醇症蕴藏着巨大的市场潜力。

肿瘤治疗的新范式：将 siRNA 与 PD-1 抑制剂（例如 Arrowhead 的 ARO-HIF2）结合使用，在肾癌治疗中显示出协同效应，引领肿瘤免疫疗法进入基因调控时代。

个人化医疗的兴起：基于基因型的siRNA疗法（例如，针对携带APOE4突变患者的阿兹海默症治疗）满足了精准医疗的需求，并提高了患者的支付意愿。

3. 政策支持：完善全球法规结构

中国的政策红利

《「十四五」医药产业发展计画》明确支持新型递送系统和核酸药物的研发，提供税收优惠和研发补助。

优先审查通道：中国国家药品监督管理局（CDE）正在对被认定为突破性治疗方法的创新siRNA药物实施快速核准，例如Sirnaomics公司的STP705（用于治疗鳞状细胞皮肤癌）。

国际监管合作

FDA加速核准：Onpattro（2018年）成为首个核准监管部门批准的siRNA药物。

EMA 适应性核准途径：允许基于替代终点（例如生物标记变化）进行有条件核准，以缩短研发週期。

4. 资本流入：产业生态系的催化作用

活性化投资和资金筹措活动

全球资本部署：2022 年，小分子核酸药物领域共有 33 笔资金筹措，总额约 60 亿美元（例如，Sirnaomics 的 IPO 筹集了 1.5 亿美元）。

大型跨国企业纷纷加入竞争：罗氏以 28 亿美元收购 Dicerna，诺华和 Alnylam 以 35 亿美元合作加速产品线开发。

CDMO服务生态系的成熟

锐博生物、无锡艾普泰克：提供从序列设计到 cGMP 生产的「一站式」服务，降低研发成本 50% 以上。

大规模生产取得突破：连续流合成技术已将 siRNA 的年产量从克级扩大到公斤级，并将每批的成本降低到 100 美元以下。

5. 竞争格局：从技术壁垒到生态学壁垒

专利布局改进

递送系统核心专利：Alnylam 拥有丛集关键技术专利，包括 LNP 和 GalNAc，使其拥有技术垄断地位。

化学修饰专利网络：Ionis 的 2'-MOE 修饰和 Sirnaomics 的 GalNAc-siRNA 偶联技术形成专利护城河。

跨境合作加速

製药和生物技术合作：例如，Astra Zeneca和 Silence Therapeutics 正在合作开发心血管 siRNA 药物，共用研发的风险和效益。

透过产学研合作实现协同创新：哈佛大学和 Moderna 正在合作开发 RNA 编辑技术，加速基础研究向临床应用的转化。

6. 挑战与解决方案

克服技术挑战

渗透性：透过细胞渗透性肽 (CPP) 修饰和外泌体递送技术，克服了 siRNA 在肺部和脑部等器官中递送的挑战。

长期安全性评估：将建立即时定量PCR来监测脱靶效应，并结合单细胞定序技术优化序列设计。

成本效益平衡

分级定价策略：在低收入国家，将采用「专利联盟」模式（如药品价格协议）来改善药品的可及性。

未来，siRNA药物有望成为继小分子药物和抗体医药品之后的第三大类药物，重塑生物製药产业的模式。企业需要专注于核心技术的突破、差异化适应症的开发以及全球合作，以掌握市场机会。

本报告旨在按地区/国家、类型和应用对全球siRNA药物市场进行全面分析，重点关注总销售额、市场份额和主要企业的排名。

本报告以销售收入为指标，对siRNA药物市场规模、估算和预测进行了呈现，以2024年为基准年，并涵盖了2020年至2031年的历史数据和预测数据。透过定量和定性分析，我们旨在帮助读者制定业务/成长策略，评估竞争格局，分析公司在当前市场中的地位，并就siRNA药物做出明智的商业决策。

市场区隔

公司

  • Alnylam
  • Novartis
  • Novo Nordisk
  • Genzyme
  • Arrowhead
  • Silence
  • Sylentis
  • Avidity Biosciences
  • Sirnaomics

按类型分類的细分市场

  • 静脉注射
  • 皮下注射

应用领域

  • 神经系统治疗
  • 内分泌和代谢疗法
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for siRNA Drugs was estimated to be worth US$ 2443 million in 2024 and is forecast to a readjusted size of US$ 16238 million by 2031 with a CAGR of 28.9% during the forecast period 2025-2031.

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20-24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.

Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.

In-depth analysis of siRNA drug market driving factors

I. Technological breakthroughs: the leap from laboratory to clinic

Delivery system innovation

Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.

Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.

Mature chemical modification technology

Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.

Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.

2. Market demand: The outbreak of unmet clinical needs

Indications expand from rare diseases to common diseases

Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.

New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.

The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.

3. Policy support: Improvement of the global regulatory framework

China's policy dividends

"The 14th Five-Year Plan for the Development of the Pharmaceutical Industry": Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.

Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.

International regulatory coordination

FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.

EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.

4. Capital influx: catalytic effect of industrial ecology

Increased investment and financing activity

Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).

MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.

CDMO service ecosystem matures

RiboBio, WuXi AppTec: Provide "one-stop" services from sequence design to cGMP production, reducing R&D costs by more than 50%.

Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.

5. Competitive landscape: From technical barriers to ecological barriers

Strengthening of patent layout

Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.

Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.

Cross-border cooperation is accelerating

Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.

Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.

6. Challenges and coping strategies

Breakthrough in technical bottlenecks

Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.

Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.

Balance between cost and accessibility

Tiered pricing strategy: Adopt the "patent pool" model (such as MPP) in low-income countries to improve drug accessibility.

In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.

This report aims to provide a comprehensive presentation of the global market for siRNA Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of siRNA Drugs by region & country, by Type, and by Application.

The siRNA Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding siRNA Drugs.

Market Segmentation

By Company

  • Alnylam
  • Novartis
  • Novo Nordisk
  • Genzyme
  • Arrowhead
  • Silence
  • Sylentis
  • Avidity Biosciences
  • Sirnaomics

Segment by Type

  • Intravenous Injection
  • Subcutaneous Injection

Segment by Application

  • Nervous System Therapy
  • Endocrine and Metabolic Therapy
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of siRNA Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of siRNA Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of siRNA Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 siRNA Drugs Product Introduction
  • 1.2 Global siRNA Drugs Market Size Forecast (2020-2031)
  • 1.3 siRNA Drugs Market Trends & Drivers
    • 1.3.1 siRNA Drugs Industry Trends
    • 1.3.2 siRNA Drugs Market Drivers & Opportunity
    • 1.3.3 siRNA Drugs Market Challenges
    • 1.3.4 siRNA Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global siRNA Drugs Players Revenue Ranking (2024)
  • 2.2 Global siRNA Drugs Revenue by Company (2020-2025)
  • 2.3 Key Companies siRNA Drugs Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies siRNA Drugs Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of siRNA Drugs
  • 2.6 siRNA Drugs Market Competitive Analysis
    • 2.6.1 siRNA Drugs Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by siRNA Drugs Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drugs as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Intravenous Injection
    • 3.1.2 Subcutaneous Injection
  • 3.2 Global siRNA Drugs Sales Value by Type
    • 3.2.1 Global siRNA Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global siRNA Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global siRNA Drugs Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Nervous System Therapy
    • 4.1.2 Endocrine and Metabolic Therapy
    • 4.1.3 Others
  • 4.2 Global siRNA Drugs Sales Value by Application
    • 4.2.1 Global siRNA Drugs Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global siRNA Drugs Sales Value, by Application (2020-2031)
    • 4.2.3 Global siRNA Drugs Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global siRNA Drugs Sales Value by Region
    • 5.1.1 Global siRNA Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global siRNA Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global siRNA Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global siRNA Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America siRNA Drugs Sales Value, 2020-2031
    • 5.2.2 North America siRNA Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe siRNA Drugs Sales Value, 2020-2031
    • 5.3.2 Europe siRNA Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific siRNA Drugs Sales Value, 2020-2031
    • 5.4.2 Asia Pacific siRNA Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America siRNA Drugs Sales Value, 2020-2031
    • 5.5.2 South America siRNA Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa siRNA Drugs Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa siRNA Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions siRNA Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions siRNA Drugs Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States siRNA Drugs Sales Value, 2020-2031
    • 6.3.2 United States siRNA Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States siRNA Drugs Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe siRNA Drugs Sales Value, 2020-2031
    • 6.4.2 Europe siRNA Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe siRNA Drugs Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China siRNA Drugs Sales Value, 2020-2031
    • 6.5.2 China siRNA Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China siRNA Drugs Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan siRNA Drugs Sales Value, 2020-2031
    • 6.6.2 Japan siRNA Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan siRNA Drugs Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea siRNA Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea siRNA Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea siRNA Drugs Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia siRNA Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia siRNA Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia siRNA Drugs Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India siRNA Drugs Sales Value, 2020-2031
    • 6.9.2 India siRNA Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India siRNA Drugs Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Alnylam
    • 7.1.1 Alnylam Profile
    • 7.1.2 Alnylam Main Business
    • 7.1.3 Alnylam siRNA Drugs Products, Services and Solutions
    • 7.1.4 Alnylam siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Alnylam Recent Developments
  • 7.2 Novartis
    • 7.2.1 Novartis Profile
    • 7.2.2 Novartis Main Business
    • 7.2.3 Novartis siRNA Drugs Products, Services and Solutions
    • 7.2.4 Novartis siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Novartis Recent Developments
  • 7.3 Novo Nordisk
    • 7.3.1 Novo Nordisk Profile
    • 7.3.2 Novo Nordisk Main Business
    • 7.3.3 Novo Nordisk siRNA Drugs Products, Services and Solutions
    • 7.3.4 Novo Nordisk siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Novo Nordisk Recent Developments
  • 7.4 Genzyme
    • 7.4.1 Genzyme Profile
    • 7.4.2 Genzyme Main Business
    • 7.4.3 Genzyme siRNA Drugs Products, Services and Solutions
    • 7.4.4 Genzyme siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Genzyme Recent Developments
  • 7.5 Arrowhead
    • 7.5.1 Arrowhead Profile
    • 7.5.2 Arrowhead Main Business
    • 7.5.3 Arrowhead siRNA Drugs Products, Services and Solutions
    • 7.5.4 Arrowhead siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Arrowhead Recent Developments
  • 7.6 Silence
    • 7.6.1 Silence Profile
    • 7.6.2 Silence Main Business
    • 7.6.3 Silence siRNA Drugs Products, Services and Solutions
    • 7.6.4 Silence siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Silence Recent Developments
  • 7.7 Sylentis
    • 7.7.1 Sylentis Profile
    • 7.7.2 Sylentis Main Business
    • 7.7.3 Sylentis siRNA Drugs Products, Services and Solutions
    • 7.7.4 Sylentis siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Sylentis Recent Developments
  • 7.8 Avidity Biosciences
    • 7.8.1 Avidity Biosciences Profile
    • 7.8.2 Avidity Biosciences Main Business
    • 7.8.3 Avidity Biosciences siRNA Drugs Products, Services and Solutions
    • 7.8.4 Avidity Biosciences siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Avidity Biosciences Recent Developments
  • 7.9 Sirnaomics
    • 7.9.1 Sirnaomics Profile
    • 7.9.2 Sirnaomics Main Business
    • 7.9.3 Sirnaomics siRNA Drugs Products, Services and Solutions
    • 7.9.4 Sirnaomics siRNA Drugs Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Sirnaomics Recent Developments

8 Industry Chain Analysis

  • 8.1 siRNA Drugs Industrial Chain
  • 8.2 siRNA Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 siRNA Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 siRNA Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. siRNA Drugs Market Trends
  • Table 2. siRNA Drugs Market Drivers & Opportunity
  • Table 3. siRNA Drugs Market Challenges
  • Table 4. siRNA Drugs Market Restraints
  • Table 5. Global siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global siRNA Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies siRNA Drugs Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies siRNA Drugs Product Type
  • Table 9. Key Companies Time to Begin Mass Production of siRNA Drugs
  • Table 10. Global siRNA Drugs Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drugs as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global siRNA Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global siRNA Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global siRNA Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global siRNA Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global siRNA Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global siRNA Drugs Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global siRNA Drugs Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global siRNA Drugs Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global siRNA Drugs Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global siRNA Drugs Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global siRNA Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global siRNA Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global siRNA Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global siRNA Drugs Sales Value by Region (2020-2025) & (%)
  • Table 27. Global siRNA Drugs Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions siRNA Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions siRNA Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions siRNA Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Alnylam Basic Information List
  • Table 32. Alnylam Description and Business Overview
  • Table 33. Alnylam siRNA Drugs Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in siRNA Drugs Business of Alnylam (2020-2025)
  • Table 35. Alnylam Recent Developments
  • Table 36. Novartis Basic Information List
  • Table 37. Novartis Description and Business Overview
  • Table 38. Novartis siRNA Drugs Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in siRNA Drugs Business of Novartis (2020-2025)
  • Table 40. Novartis Recent Developments
  • Table 41. Novo Nordisk Basic Information List
  • Table 42. Novo Nordisk Description and Business Overview
  • Table 43. Novo Nordisk siRNA Drugs Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in siRNA Drugs Business of Novo Nordisk (2020-2025)
  • Table 45. Novo Nordisk Recent Developments
  • Table 46. Genzyme Basic Information List
  • Table 47. Genzyme Description and Business Overview
  • Table 48. Genzyme siRNA Drugs Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in siRNA Drugs Business of Genzyme (2020-2025)
  • Table 50. Genzyme Recent Developments
  • Table 51. Arrowhead Basic Information List
  • Table 52. Arrowhead Description and Business Overview
  • Table 53. Arrowhead siRNA Drugs Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in siRNA Drugs Business of Arrowhead (2020-2025)
  • Table 55. Arrowhead Recent Developments
  • Table 56. Silence Basic Information List
  • Table 57. Silence Description and Business Overview
  • Table 58. Silence siRNA Drugs Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in siRNA Drugs Business of Silence (2020-2025)
  • Table 60. Silence Recent Developments
  • Table 61. Sylentis Basic Information List
  • Table 62. Sylentis Description and Business Overview
  • Table 63. Sylentis siRNA Drugs Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in siRNA Drugs Business of Sylentis (2020-2025)
  • Table 65. Sylentis Recent Developments
  • Table 66. Avidity Biosciences Basic Information List
  • Table 67. Avidity Biosciences Description and Business Overview
  • Table 68. Avidity Biosciences siRNA Drugs Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in siRNA Drugs Business of Avidity Biosciences (2020-2025)
  • Table 70. Avidity Biosciences Recent Developments
  • Table 71. Sirnaomics Basic Information List
  • Table 72. Sirnaomics Description and Business Overview
  • Table 73. Sirnaomics siRNA Drugs Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in siRNA Drugs Business of Sirnaomics (2020-2025)
  • Table 75. Sirnaomics Recent Developments
  • Table 76. Key Raw Materials Lists
  • Table 77. Raw Materials Key Suppliers Lists
  • Table 78. siRNA Drugs Downstream Customers
  • Table 79. siRNA Drugs Distributors List
  • Table 80. Research Programs/Design for This Report
  • Table 81. Key Data Information from Secondary Sources
  • Table 82. Key Data Information from Primary Sources

List of Figures

  • Figure 1. siRNA Drugs Product Picture
  • Figure 2. Global siRNA Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global siRNA Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. siRNA Drugs Report Years Considered
  • Figure 5. Global siRNA Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by siRNA Drugs Revenue in 2024
  • Figure 7. siRNA Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Intravenous Injection Picture
  • Figure 9. Subcutaneous Injection Picture
  • Figure 10. Global siRNA Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global siRNA Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Nervous System Therapy
  • Figure 13. Product Picture of Endocrine and Metabolic Therapy
  • Figure 14. Product Picture of Others
  • Figure 15. Global siRNA Drugs Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global siRNA Drugs Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America siRNA Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America siRNA Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe siRNA Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific siRNA Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America siRNA Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Middle East & Africa siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Middle East & Africa siRNA Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Key Countries/Regions siRNA Drugs Sales Value (%), (2020-2031)
  • Figure 28. United States siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. United States siRNA Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 30. United States siRNA Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 31. Europe siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe siRNA Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 33. Europe siRNA Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 34. China siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. China siRNA Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 36. China siRNA Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Japan siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Japan siRNA Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Japan siRNA Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 40. South Korea siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. South Korea siRNA Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 42. South Korea siRNA Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Southeast Asia siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Southeast Asia siRNA Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Southeast Asia siRNA Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 46. India siRNA Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. India siRNA Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 48. India siRNA Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 49. siRNA Drugs Industrial Chain
  • Figure 50. siRNA Drugs Manufacturing Cost Structure
  • Figure 51. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 52. Bottom-up and Top-down Approaches for This Report
  • Figure 53. Data Triangulation
  • Figure 54. Key Executives Interviewed